CRECON genomics

Improving
Health Through
Genomics

About

Crecon Genomics is contributing in the fields of cancer prevention, early detection, and treatment, as well as working to advance the selection of therapeutic drugs based on individual genomic data and the latest in domestic and international research.

The importance and social significance of cancer prevention is increasing worldwide. In accordance with our company’s vision to deliver more accurate and faster technologies which can reach more people: In cooperation with domestic and international research institutes, medical institutions, and our partner companies, we aim to deliver the latest in diagnostic technologies.

Utilizing the latest
in preventive medicine
and DNA analysis technologies,
we aim to establish and popularize
new diagnostic methods.

Information

Company

Corporate Name Crecon Genomics Inc.
Business Genomic Medicine Information Services.
Established April 12, 2023
Address 405, Miyamasuzaka Building 2-19-15 Shibuya,
Shibuya-ku, Tokyo 150-0002, Japan.

Location

405, Miyamasuzaka Building 2-19-15 Shibuya,
Shibuya-ku, Tokyo 150-0002, Japan.

Board of Directors

Hitoshi Kimura Representative Director and
Chairman
Toshiaki Ito President & Chief Executive
Officer
Takashi Tsuchiya Board Director,
Executive Vice-President
Tetsuji Matsuyama Board Director,
Chief Operation Officer
Takuro Tamura Board Director,
Chief Information Officer
Teruyoshi Hishiki Board Director,
Chief Science Officer
Takaaki Sato Independent Director
Tsuyoshi Nishitani Auditor

Affiliates

Partner

Partner
iLAC is a genuinely unique entity devoted to fertile promotion of “precision medicine” (meticulously individualized medical procedures), which facilitates selection of optimum treatments, medications, and other advances tailored to the needs of specific patients. With that vision in mind, iLAC provides high-throughput genome analysis, expression analysis, and genome structure analysis applied to multiple specimens. Likewise mobilized are proteome, metabolomic, and other omics analysis networks effective in formulating pathological evaluation systems on the strength of multidimensional markers.Employing its high value-added, extensive and detailed databases, the laboratory contributes to the discovery of new therapeutic targets, fulfillment of healthy longevity against the backdrop of today’s aging society, and feasible curbs on healthcare costs.